MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Champions Oncology Inc

Geschlossen

BrancheGesundheitswesen

7.86 -4.26

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

7.64

Max

8.26

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.8M

4.5M

Verkäufe

3.6M

17M

KGV

Branchendurchschnitt

17.711

39.857

Gewinnspanne

26.381

Angestellte

210

EBITDA

3.8M

4.9M

Dividenden

By Dow Jones

Nächstes Ergebnis

10. Sept. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-25M

110M

Vorheriger Eröffnungskurs

12.12

Vorheriger Schlusskurs

7.86

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Champions Oncology Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Dez. 2024, 23:55 UTC

Heiße Aktien

Stocks to Watch: Adobe, Champions Oncology, DBV Technologies

Peer-Vergleich

Kursveränderung

Champions Oncology Inc Prognose

Rating-Konsens

By TipRanks

0 ratings

0

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

5.77 / 7.61Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Very Strong Bearish Evidence

Langfristig

Strong Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Champions Oncology Inc

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.